FTPA advised NextStage AM, a leading player in growth capital in France, and Eurobionext, a joint investment vehicle established in 2022 with entrepreneurs at the time of NextStage AM’s entry into the capital, in connection with the public tender offer launched by EB Development for Eurobio Scientific, a European leader in in vitro diagnostic solutions. This strategic transaction marks a key milestone for Eurobio Scientific, which will benefit from the support of NextStage AM and IK Partners to accelerate its growth in a rapidly expanding sector.
Eurobio Scientific, listed on Euronext Growth Paris, is a key player in medical diagnostics, particularly renowned for its expertise in molecular biology and its innovative solutions in areas such as infectious diseases, immunology, and oncology. With this acquisition, the company enhances its ability to provide cutting-edge solutions to laboratories and hospitals across Europe.
Already a shareholder in Eurobio Scientific since May 2022 through its holding company “EurobioNext” and actively involved in the company’s development since 2022 via its “Pépites et Territoires” program by AXA France & NextStage AM, the investment management firm continues to play a pivotal role in the company’s growth, in partnership with IK Partners.
Through this transaction, NextStage AM confirms its commitment to supporting innovative companies in their growth and transformation strategies, leveraging its long-term investment approach.
FTPA advised NextStage AM with a dedicated corporate team led by François-Xavier Beauvisage (partner), Mayssa Sader, and Olivier Lang.
